Skip to main content
. Author manuscript; available in PMC: 2015 Apr 1.
Published in final edited form as: J Thorac Oncol. 2014 Apr;9(4):559–562. doi: 10.1097/JTO.0000000000000079

Figure 1.

Figure 1

Figure 1

A. Time to progression

Kaplan-Meier curve showing time to progression (TTP) with 95% C.I. of 50 patients treated with bendamustine for relapsed small cell lung cancer (SCLC). The median TTP in this population was 4.0 months (95% C.I. 3.3–5.4 months).

B. Time to progression in chemosensitive and chemoresistant disease

Kaplan-Meier curves showing time to progression (TTP) with 95% C.I. of 29 patients treated with bendamustine for relapsed small cell lung cancer (SCLC) with chemosensitive disease and TTP with 95% C.I. of 21 patients treated with bendamustine for relapsed SCLC with chemoresistant disease. The median TTP in patients with chemosensitive disease was 4.2 months (95% C.I. 3.3–6.0 months) and those with chemoresistant disease had a median TTP of 3.4 months (95% C.I. 2.7–‡ months). There was no difference in median TTP between the two groups (p=0.41).